PATENT CLAIM ANALYSIS

Application Number: 16109562
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-08
Patent Classification: ["514", "290000"]

Abstract:
The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.

Claim (Index 2):
The method of  claim 1 , wherein the compound is administered in a pharmaceutical composition which further comprises a pharmaceutically acceptable excipient.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 96.0
- Lexical Diversity: 1.16
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['10861082', '15133104', '12015275', '11442727', '13599161']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8300218955675687
- 35 USC 102 Novelty (BERT): 0.6192883948835789
- Combined Prediction Score: 0.8089485454991697
- Mean Citation Score: 509.981424
- Max Citation Score: 539.677
- Similarity Product: 528.3074512425064

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test